SUPN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
219.1M
+5.5%
207.7M
-1.8%
211.6M
+10.1%
192.1M
+16.1%
165.5M
Cost of Revenue
33.7M
+43.9%
23.4M
+1.7%
23.0M
+21.3%
19.0M
+12.7%
16.8M
Gross Profit
185.4M
+0.6%
184.3M
-2.3%
188.6M
+8.9%
173.1M
+16.5%
148.6M
Operating Expenses
243.4M
+26.3%
192.6M
+0.1%
192.5M
-17.5%
233.4M
+71.0%
136.5M
R&D
29.5M
-25.3%
39.4M
+41.7%
27.8M
-5.2%
29.4M
+32.8%
22.1M
SG&A
133.6M
+6.8%
125.2M
+2.3%
122.4M
-31.9%
179.7M
+92.1%
93.6M
Operating Income
-57963000
-595.7%
-8332000
-111.6%
-3937000
+93.5%
-60231000
-596.1%
12.1M
EBITDA
22.7M
+12.4%
20.2M
-4.2%
21.1M
+159.5%
-35425000
-205.7%
33.5M
Net Income
-58371000
-2445.6%
-2293000
+44.1%
-4105000
+90.9%
-45117000
-300.5%
22.5M
EPS (Basic)
$-1.01
-2425.0%
$-0.04
+42.9%
$-0.07
+91.3%
$-0.80
-300.0%
$0.40
EPS (Diluted)
$-1.01
-2425.0%
$-0.04
+42.9%
$-0.07
+91.3%
$-0.80
-300.0%
$0.40
Shares (Diluted)
58.1M
+0.7%
57.6M
+1.6%
56.7M
+0.3%
56.6M
-0.2%
56.6M
Supernus Pharmaceuticals (SUPN) โ€” Financials